Sprint Bioscience Past Earnings Performance
Past criteria checks 4/6
Sprint Bioscience has been growing earnings at an average annual rate of 13.4%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 18.4% per year. Sprint Bioscience's return on equity is 78.7%, and it has net margins of 17.1%.
Key information
13.4%
Earnings growth rate
41.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 18.4% |
| Return on equity | 78.7% |
| Net Margin | 17.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sprint Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 86 | 15 | 52 | 0 |
| 31 Mar 24 | 70 | 9 | 48 | 0 |
| 31 Dec 23 | 52 | 0 | 45 | 0 |
| 30 Sep 23 | 40 | -10 | 45 | 0 |
| 30 Jun 23 | 0 | -52 | 44 | 0 |
| 31 Mar 23 | 0 | -58 | 47 | 0 |
| 31 Dec 22 | 0 | -60 | 47 | 0 |
| 30 Sep 22 | 1 | -60 | 48 | 0 |
| 30 Jun 22 | 35 | -30 | 51 | 0 |
| 31 Mar 22 | 35 | -26 | 49 | 0 |
| 31 Dec 21 | 35 | -25 | 49 | 0 |
| 30 Sep 21 | 35 | -25 | 49 | 0 |
| 30 Jun 21 | 8 | -48 | 46 | 0 |
| 31 Mar 21 | 14 | -47 | 45 | 0 |
| 31 Dec 20 | 19 | -43 | 46 | 0 |
| 30 Sep 20 | 23 | -39 | 47 | 0 |
| 30 Jun 20 | 21 | -40 | 48 | 0 |
| 31 Mar 20 | 35 | -23 | 48 | 0 |
| 31 Dec 19 | 34 | -22 | 45 | 0 |
| 30 Sep 19 | 21 | -31 | 42 | 0 |
| 30 Jun 19 | 19 | -33 | 41 | 0 |
| 31 Mar 19 | 3 | -47 | 39 | 0 |
| 31 Dec 18 | 18 | -32 | 39 | 0 |
| 30 Sep 18 | 31 | -19 | 37 | 0 |
| 30 Jun 18 | 32 | -15 | 35 | 0 |
| 31 Mar 18 | 41 | -5 | 34 | 0 |
| 31 Dec 17 | 33 | -11 | 32 | 0 |
| 30 Sep 17 | 41 | -1 | 30 | 0 |
| 30 Jun 17 | 47 | 5 | 31 | 0 |
| 31 Mar 17 | 53 | 8 | 31 | 0 |
| 31 Dec 16 | 47 | 5 | 30 | 0 |
| 30 Sep 16 | 40 | -2 | 30 | 0 |
| 30 Jun 16 | 34 | -5 | 28 | 0 |
| 31 Mar 16 | 17 | -14 | 25 | 0 |
| 31 Dec 15 | 13 | -15 | 23 | 0 |
| 30 Sep 15 | 10 | -15 | 20 | 0 |
| 30 Jun 15 | 6 | -15 | 16 | 0 |
| 31 Mar 15 | 6 | -13 | 14 | 0 |
| 31 Dec 14 | 5 | -11 | 13 | 0 |
| 30 Sep 14 | 5 | -9 | 11 | 0 |
| 30 Jun 14 | 5 | -7 | 10 | 0 |
| 31 Mar 14 | 6 | -6 | 11 | 0 |
| 31 Dec 13 | 8 | -4 | 11 | 0 |
Quality Earnings: 5JA1 has high quality earnings.
Growing Profit Margin: 5JA1 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 5JA1 has become profitable over the past 5 years, growing earnings by 13.4% per year.
Accelerating Growth: 5JA1 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 5JA1 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 5JA1's Return on Equity (78.7%) is considered outstanding.